Effects of participation in a U.S. trial of newborn genomic sequencing on parents at risk for depression

Much emphasis has been placed on participant's psychological safety within genomic research studies; however, few studies have addressed parental psychological health effects associated with their child's participation in genomic studies, particularly when parents meet the threshold for clinical concern for depression. We aimed to determine if parents’ depressive symptoms were associated with their child's participation in a randomized‐controlled trial of newborn exome sequencing. Parents completed the Edinburgh Postnatal Depression Scale (EPDS) at baseline, immediately post‐disclosure, and 3 months post‐disclosure. Mothers and fathers scoring at or above thresholds for clinical concern on the EPDS, 12 and 10, respectively, indicating possible Major Depressive Disorder with Peripartum Onset, were contacted by study staff for mental health screening. Parental concerns identified in follow‐up conversations were coded for themes. Forty‐five parents had EPDS scores above the clinical threshold at baseline, which decreased by an average of 2.9 points immediately post‐disclosure and another 1.1 points 3 months post‐disclosure (both p ≤ .014). For 28 parents, EPDS scores were below the threshold for clinical concern at baseline, increased by an average of 4.7 points into the elevated range immediately post‐disclosure, and decreased by 3.8 points at 3 months post‐disclosure (both p < .001). Nine parents scored above thresholds only at 3 months post‐disclosure after increasing an average of 5.7 points from immediately post‐disclosure (p < .001). Of the 82 parents who scored above the threshold at any time point, 43 (52.4%) were reached and 30 (69.7%) of these 43 parents attributed their elevated scores to parenting stress, balancing work and family responsibilities, and/or child health concerns. Only three parents (7.0%) raised concerns about their participation in the trial, particularly their randomization to the control arm. Elevated scores on the EPDS were typically transient and parents attributed their symptomatology to life stressors in the postpartum period rather than participation in a trial of newborn exome sequencing.

[1]  Denise L. Perry,et al.  Disclosing genetic risk for Alzheimer's dementia to individuals with mild cognitive impairment , 2020, Alzheimer's & Dementia.

[2]  W. Chung,et al.  Psychological outcomes related to exome and genome sequencing result disclosure: a meta-analysis of seven Clinical Sequencing Exploratory Research (CSER) Consortium studies , 2019, Genetics in Medicine.

[3]  J. Cox Thirty years with the Edinburgh Postnatal Depression Scale: voices from the past and recommendations for the future , 2019, The British Journal of Psychiatry.

[4]  R. Green,et al.  Perceived Benefits, Risks, and Utility of Newborn Genomic Sequencing in the BabySeq Project , 2019, Pediatrics.

[5]  M. Yogman,et al.  Incorporating Recognition and Management of Perinatal Depression Into Pediatric Practice , 2018, Pediatrics.

[6]  M. Yogman,et al.  Incorporating Recognition and Management of Perinatal Depression Into Pediatric Practice , 2018, Pediatrics.

[7]  ACOG Committee Opinion No. 757: Screening for Perinatal Depression. , 2018, Obstetrics and gynecology.

[8]  A. Boström,et al.  New parents' experience of information and sense of security related to postnatal care: A systematic review. , 2018, Sexual & reproductive healthcare : official journal of the Swedish Association of Midwives.

[9]  Ebony B Madden,et al.  Opportunities to implement a sustainable genomic medicine program: lessons learned from the IGNITE Network , 2018, Genetics in Medicine.

[10]  R. Green,et al.  The BabySeq project: implementing genomic sequencing in newborns , 2018, BMC Pediatrics.

[11]  E. Parens,et al.  Sequencing Newborns: A Call for Nuanced Use of Genomic Technologies. , 2018, The Hastings Center report.

[12]  M. Edhborg,et al.  Paternal Perinatal Depression Assessed by the Edinburgh Postnatal Depression Scale and the Gotland Male Depression Scale: Prevalence and Possible Risk Factors , 2018, American journal of men's health.

[13]  Ebony B Madden,et al.  Developing a Common Framework for Evaluating the Implementation of Genomic Medicine Interventions in Clinical Care: The IGNITE Network’s Common Measures Working Group , 2017, Genetics in Medicine.

[14]  Rosalind J Wright,et al.  Subconstructs of the Edinburgh Postnatal Depression Scale in a multi-ethnic inner-city population in the U.S. , 2017, Archives of Women's Mental Health.

[15]  S. Wheeler,et al.  Screening for and Treating Postpartum Depression and Psychosis: A Cost-Effectiveness Analysis , 2017, Maternal and Child Health Journal.

[16]  Tiina K. Urv,et al.  Newborn Sequencing in Genomic Medicine and Public Health , 2017, Pediatrics.

[17]  Matthew S. Lebo,et al.  A curated gene list for reporting results of newborn genomic sequencing , 2017, Genetics in Medicine.

[18]  S. Matthey,et al.  Using the Edinburgh Postnatal Depression Scale for women and men—some cautionary thoughts , 2017, Archives of Women's Mental Health.

[19]  W. Chung,et al.  Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics , 2016, Genetics in Medicine.

[20]  I. Hallström,et al.  First-time parents' prenatal needs for early parenthood preparation-A systematic review and meta-synthesis of qualitative literature. , 2016, Midwifery.

[21]  Deepak L. Bhatt,et al.  Disclosing Pleiotropic Effects During Genetic Risk Assessment for Alzheimer Disease: A Randomized Trial. , 2016, Annals of internal medicine.

[22]  A. McGuire,et al.  Potential Psychosocial Risks of Sequencing Newborns , 2016, Pediatrics.

[23]  Diane Hauser,et al.  The IGNITE network: a model for genomic medicine implementation and research , 2015, BMC Medical Genomics.

[24]  Deepak L. Bhatt,et al.  A randomized noninferiority trial of condensed protocols for genetic risk disclosure of Alzheimer's disease , 2015, Alzheimer's & Dementia.

[25]  J. Veltman,et al.  Patient experiences with gene panels based on exome sequencing in clinical diagnostics: high acceptance and low distress , 2015, Clinical Genetics.

[26]  Laura J. Bierut,et al.  Return of individual genetic results in a high-risk sample: enthusiasm and positive behavioral change , 2014, Genetics in Medicine.

[27]  Isaac S Kohane,et al.  The MedSeq Project: a randomized trial of integrating whole genome sequencing into clinical medicine , 2014, Trials.

[28]  A. McGuire,et al.  Social and behavioral research in genomic sequencing: approaches from the Clinical Sequencing Exploratory Research Consortium Outcomes and Measures Working Group , 2014, Genetics in Medicine.

[29]  K. Helzlsouer,et al.  Primary care patients’ views and decisions about, experience of and reactions to direct-to-consumer genetic testing: a longitudinal study , 2013, Journal of Community Genetics.

[30]  Eric J Topol,et al.  Impact of direct-to-consumer genomic testing at long term follow-up , 2013, Journal of Medical Genetics.

[31]  S. J. McCoy,et al.  Postpartum Depression in Men , 2012 .

[32]  N. Schork,et al.  Effect of direct-to-consumer genomewide profiling to assess disease risk. , 2011, The New England journal of medicine.

[33]  Robert Cook-Deegan,et al.  Disclosure of APOE genotype for risk of Alzheimer's disease. , 2009, The New England journal of medicine.

[34]  J. Cox,et al.  Detection of Postnatal Depression , 1987, British Journal of Psychiatry.

[35]  D. Stewart,et al.  Postpartum Depression. , 2016, The New England journal of medicine.

[36]  Brenda Wilson,et al.  A systematic review of perceived risks, psychological and behavioral impacts of genetic testing , 2008, Genetics in Medicine.

[37]  K. W. Backe,et al.  [In the children's hospital]. , 1984, Krankenpflege Journal.

[38]  K. Buckwalter,et al.  Postpartum depression. , 1983, Maternal-child nursing journal.

[39]  H. Rubash MASSACHUSETTS General Hospital. , 1957, Medical times.